Placement Agency Agreement Sample Contracts

Oculus Innovative Sciences – Placement Agency Agreement (November 21st, 2018)

This letter (this "Agreement") constitutes the agreement between Sonoma Pharmaceuticals Inc., a Delaware corporation (the "Company"), and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

Placement Agency Agreement (November 13th, 2018)
IntelGenx Technologies Corp. – Canadian Placement Agency Agreement (October 22nd, 2018)

Subject to the terms and conditions herein (this Agreement), IntelGenx Technologies Corp., a Delaware corporation (the Company), hereby agrees to sell up to an aggregate of up to $12,001,020 of registered securities of the Company, including, but not limited to, up to 17,144,314 shares (the Shares) of the Companys common stock, $0.00001 par value per share (the "Common Stock), and up to 8,572,157 Common Stock purchase warrants to purchase shares of Common Stock (the Warrants and the shares of Common Stock underlying the Warrants, the Warrant Shares, directly to various investors (each, an Investor and, collectively, the Investors and the Investors in the United States, the U.S. Investors) through H.C. Wainwright & Co., LLC (Wainwright or U.S. Placement Agent) pursuant to a separate placement agency agreement (U.S. PAA), and through Echelon Wealth Partners Inc. (Echelon or Canada Placement Agent) (the U.S. Placement Agent and Canada Placement Agent, collectively, the Placement Agents) i

Placement Agency Agreement (October 11th, 2018)

This letter (the "Agreement") constitutes the agreement among Maxim Group LLC ("Maxim" or the "Placement Agent") and MagneGas Applied Technology Solutions, Inc. (the "Company"), that the Placement Agent shall serve as the exclusive placement agent for the Company, on a "reasonable best efforts" basis, in connection with the proposed placement (the "Placement") of shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock") and warrants to purchase shares of Common Stock (the "Warrants"). The Shares, the Warrants and the shares of Common Stock underlying the Warrants (the "Warrant Shares") are hereinafter referred to collectively as the "Securities"). The Securities are being offered pursuant to the registration statement on Form S-3 (File No. 333-207928)(the "Registration Statement", and the prospectus contained therein, the "Prospectus") initially filed by the Company with the Securities and Exchange Commission (the "SEC") under the Securities A

Medical Transcription Billing, Corp – Placement Agency Agreement (October 10th, 2018)
Medical Transcription Billing, Corp – Placement Agency Agreement (October 9th, 2018)
Placement Agency Agreement (October 9th, 2018)
PLACEMENT AGENCY AGREEMENT September 28, 2018 (October 4th, 2018)
Co-Placement Agency Agreement (October 3rd, 2018)
Monaker Group, Inc. – Placement Agency Agreement (October 2nd, 2018)
SONUS Pharmaceuticals, Inc. – PLACEMENT AGENCY AGREEMENT October 1, 2018 (October 1st, 2018)
Placement Agency Agreement (September 25th, 2018)
And Warrants to Purchase 5,844,445 Shares of Common Stock Placement Agency Agreement (September 20th, 2018)
Placement Agency Agreement (September 14th, 2018)
Avinger Inc – PLACEMENT AGENCY AGREEMENT July 12, 2018 (July 13th, 2018)
Placement Agency Agreement (June 27th, 2018)
Sigma Labs, Inc. – Placement Agency Agreement (June 26th, 2018)

This letter (this "Agreement") constitutes the agreement between Sigma Labs, Inc., a Nevada corporation (the "Company"), and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

Moleculin Biotech, Inc. – Placement Agency Agreement (June 21st, 2018)
Matinas BioPharma Holdings, Inc. – Matinas Biopharma Holdings, Inc. (A Delaware Corporation) 8,000 Shares of Series B Convertible Preferred Stock PLACEMENT AGENCY AGREEMENT (June 19th, 2018)
Greenpro Capital Corp. – PLACEMENT AGENCY AGREEMENT Between GREENPRO CAPITAL CORP. (A Nevada Corporation) and NETWORK 1 FINANCIAL SECURITIES, INC. As Placement Agent (June 6th, 2018)

This letter (this "Agreement") constitutes the agreement between Greenpro Capital Corp., a Nevada corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of the Company, the "Company") and Network 1 Financial Securities, Inc. (the "Placement Agent") pursuant to which the Placement Agent shall serve as the Placement Agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer (the "Offering") by the Company of its Securities (as defined in Section 3 of this Agreement).

PLACEMENT AGENCY AGREEMENT May 17, 2018 (May 22nd, 2018)
Cidara Therapeutics, Inc. PLACEMENT AGENCY AGREEMENT (May 21st, 2018)
Placement Agency Agreement (May 9th, 2018)

This letter (this "Agreement") constitutes the agreement between Pareteum Corp., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

Sysorex Global Holdings Corp. – Placement Agency Agreement (April 24th, 2018)
Oragenics, Inc. – PLACEMENT AGENCY AGREEMENT April 6, 2018 (April 10th, 2018)
Mirna Therapeutics, Inc. – SYNLOGIC, INC. (A Delaware Corporation) 3,280,000 Shares of Common Stock PLACEMENT AGENCY AGREEMENT (April 6th, 2018)
Placement Agency Agreement (April 3rd, 2018)
Medical Transcription Billing, Corp – Placement Agency Agreement (April 2nd, 2018)
2,222,222 Shares of Common Stock SPHERIX INCORPORATED PLACEMENT AGENCY AGREEMENT (March 19th, 2018)
Oculus Innovative Sciences – Placement Agency Agreement (March 6th, 2018)

This letter (this "Agreement") constitutes the agreement between Sonoma Pharmaceuticals, Inc., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson") pursuant to which Dawson shall serve as the lead placement agent, and with The Benchmark Company, LLC as co-placement agent for which Dawson is acting as representative (Dawson and The Benchmark Company, LLC being collectively called the "Placement Agent") (the "Services"), for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Daws

Moleculin Biotech, Inc. – PLACEMENT AGENCY AGREEMENT February 16, 2018 (February 16th, 2018)
Sysorex Global Holdings Corp. – Placement Agency Agreement (February 16th, 2018)
Topspin Medical Inc – Placement Agency Agreement (February 1st, 2018)
Sysorex Global Holdings Corp. – Placement Agency Agreement (February 1st, 2018)
Placement Agency Agreement (January 24th, 2018)